Akebia Therapeutics, Inc.
AKBA
$1.18
$0.032.61%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -7.08% | -1.95% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -7.08% | -1.95% | |||
| Cost of Revenue | -10.54% | 6.36% | |||
| Gross Profit | -6.27% | -3.71% | |||
| SG&A Expenses | 16.66% | -10.33% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.58% | 17.22% | |||
| Operating Income | 75.53% | -235.94% | |||
| Income Before Tax | 20.53% | -1,072.73% | |||
| Income Tax Expenses | -87.51% | 64.07% | |||
| Earnings from Continuing Operations | 26.05% | -2,367.41% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 26.05% | -2,367.41% | |||
| EBIT | 75.53% | -235.94% | |||
| EBITDA | 79.88% | -220.14% | |||
| EPS Basic | 26.46% | -2,405.00% | |||
| Normalized Basic EPS | 34.95% | -862.96% | |||
| EPS Diluted | 31.93% | -2,590.00% | |||
| Normalized Diluted EPS | 34.95% | -892.31% | |||
| Average Basic Shares Outstanding | 0.63% | 0.22% | |||
| Average Diluted Shares Outstanding | 0.63% | -3.28% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||